Figure 4. HSPs as targets of the transplant immunome are translocated to the myeloma cell surface translocation after bortezomib treatment. Amo-1 myeloma cells were treated with 10 nM bortezomib for 24 hours followed by flow cytometric staining with HSP60-, HSP71-, and HSP90-directed antibodies (B). Untreated cells served as control (A). Isotype antibody or secondary antibody only served as staining control.
Figure 4

HSPs as targets of the transplant immunome are translocated to the myeloma cell surface translocation after bortezomib treatment. Amo-1 myeloma cells were treated with 10 nM bortezomib for 24 hours followed by flow cytometric staining with HSP60-, HSP71-, and HSP90-directed antibodies (B). Untreated cells served as control (A). Isotype antibody or secondary antibody only served as staining control.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal